5.60
+0.18(+3.32%)
Currency In USD
| Previous Close | 5.42 |
| Open | 5.46 |
| Day High | 5.6 |
| Day Low | 5.41 |
| 52-Week High | 9.33 |
| 52-Week Low | 4.66 |
| Volume | 150,925 |
| Average Volume | 773,937 |
| Market Cap | 721.34M |
| PE | -70 |
| EPS | -0.08 |
| Moving Average 50 Days | 6.33 |
| Moving Average 200 Days | 5.87 |
| Change | 0.18 |
If you invested $1000 in Cytek Biosciences, Inc. (CTKB) since IPO date, it would be worth $298.51 as of February 05, 2025 at a share price of $5.6. Whereas If you bought $1000 worth of Cytek Biosciences, Inc. (CTKB) shares 3 years ago, it would be worth $384.09 as of February 05, 2025 at a share price of $5.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results
GlobeNewswire Inc.
Jan 15, 2025 1:00 PM GMT
FREMONT, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2024. Cytek expects it
Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 02, 2025 1:00 PM GMT
FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in
Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025
GlobeNewswire Inc.
Dec 30, 2024 1:00 PM GMT
FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program for up to an additional aggreg